Full metadata record
DC FieldValueLanguage
dc.contributor.authorBräutigam, Michelle-
dc.contributor.authorVolken, Thomas-
dc.contributor.authorPlattner, Alexandra-
dc.contributor.authorPassweg, Jakob R.-
dc.contributor.authorHalter, Jörg P.-
dc.contributor.authorDrexler, Beatrice-
dc.contributor.authorHeim, Dominik-
dc.contributor.authorSchaub, Stefan-
dc.contributor.authorBuser, Andreas S.-
dc.contributor.authorInfanti, Laura-
dc.contributor.authorHolbro, Andreas-
dc.date.accessioned2021-11-11T11:12:03Z-
dc.date.available2021-11-11T11:12:03Z-
dc.date.issued2021-10-29-
dc.identifier.issn1473-0502de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/23442-
dc.description.abstractBackground and objectives: Antibodies (Ab) against HLA and HPA antigens play an important role in HCT. In this prospective study we evaluated prevalence and kinetics of HLA- and HPA-Ab after HCT, including a possible donor-recipient transfer and their clinical relevance in respect to platelet transfusion refractoriness (PTR). Materials and methods: Patients were consecutively recruited. Ab were determined by microbead assay technique and a mean fluorescence intensity cut-off of 1,000. Results: At baseline, 21 donors (42%) and 27 patients (54%) had HLA-Ab with a mean panel reactivity (cPRA) of 34.9 ± 29.4% and 46.1 ± 36.5%, respectively. We observed a significant higher number of HLA-Ab specificities in female donors and patients and a predominance of HLA-class I Ab. At day 0 we detected an increase of HLA-Ab (from 526 to 673) and cPRA (55.2 ± 31.9%). Thirty-six patients (72%) developed new HLA-Ab, mainly 3 weeks after HCT. In 7 patients an HLA-Ab with the same specificity as detected in the corresponding donor emerged, suggesting a possible transfer from the donor to the recipient. Overall, MFI showed a high variation. Type and number of transfusions were not associated with number and intensity of HLA-Ab (ρ: -0.05 – 0.02). Number of HLA-Ab, cPRA and intensity were not associated with PTR, which occurred in 9 patients (18%) and none had bleeding WHO > 2. Conclusions: Although a considerable number of patients have and develop HLA-Ab before and early after HCT, we found no association with PTR and bleeding and management should be individualized.de_CH
dc.language.isoende_CH
dc.publisherElsevierde_CH
dc.relation.ispartofTransfusion and Apheresis Sciencede_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectHLA antibodyde_CH
dc.subjectHPA antibodyde_CH
dc.subjectHematopoietic cell transplantationde_CH
dc.subjectMatched relatedde_CH
dc.subjectDonor derivedde_CH
dc.subject.ddc617: Chirurgiede_CH
dc.titleFrequency, reactivity and evolution of human leukocyte antigen and human platelet antigen antibodies in the setting of hematopoietic cell transplantationde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
zhaw.organisationalunitInstitut für Public Health (IPH)de_CH
dc.identifier.doi10.1016/j.transci.2021.103301de_CH
zhaw.funding.euNode_CH
zhaw.issue2de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.start103301de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume61de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Gesundheit

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.